Urgent Health Alert: Six Cases of Liver Damage Tied to Unapproved Weight Loss Drug

Rising Concerns Over Unregistered Weight-Loss Drug

A growing trend involving an unregistered weight-loss drug has raised serious health concerns, leading to a public warning after several individuals in Victoria were hospitalized due to liver damage. Since January, six cases of acute liver injury have been reported among users of an unapproved peptide product known as retatrutide or “reta.”

Dr. Caroline McElnay, Victoria’s Chief Health Officer, emphasized the risks associated with this substance. “These products have been purchased online, through friends and through social media accounts,” she stated. “Retatrutide is an experimental drug not approved for sale as a safe medical product in Australia. It is marketed widely online for muscle growth, fat loss, recovery and anti-ageing.”

Investigations are ongoing, but it is believed that similar cases may have occurred in other parts of Australia. The situation has become even more alarming with the story of a young woman who experienced a life-threatening ordeal after using the drug.

A Personal Story of Tragedy

Megan Hancocks, 32, became interested in retatrutide after seeing it on social media. However, she could not access it through legitimate channels. During a routine beauty appointment late last year, she was offered off-market peptides sourced from a Chinese manufacturer, available for cash.

She purchased a vial labeled as retatrutide, along with another peptide used for skin treatments. “I was quite small looking back now, but obviously your mind tells you otherwise,” she told ABC News. She took her first dose on Christmas Eve, followed by another just days later.

However, within a week, Ms. Hancocks was rushed to the Royal Melbourne Hospital with acute liver failure. Her symptoms included severe jaundice, nausea and vomiting, extreme fatigue, stomach swelling, and debilitating constipation. Doctors treated her for about a month and considered the possibility of a liver transplant, but her condition stabilized before the procedure was needed.

After six months, she remains on steroids to repair her liver, has been repeatedly hospitalized, is unable to work, and lives at home with her mother. “When I look in the mirror I don’t see the same person anymore and that’s been really hard,” Ms. Hancocks told ABC News.

Warnings from Health Authorities

The Therapeutic Goods Administration (TGA) has also issued a warning, urging Australians to avoid importing and using unapproved peptide products promoted online. TGA chief medical adviser Professor Robyn Langham highlighted the dangers of not knowing what is inside the vials. “There is no way of knowing how much of the peptide is in there, whether the contents are sterile or whether there are other contaminants or toxins in there that you risk administering to yourself,” she said.

“Unmarked vials, code-only labels, or missing ingredient and dosing information are major red flags.”

Dr. Michael Wright, president of the Royal Australian College of General Practitioners, supports the TGA’s actions. “There really could be risk for patients if they’re provided, particularly without medical supervision,” he told newsGP.

This incident serves as a stark reminder of the dangers associated with unregulated substances and the importance of seeking medical advice before trying any new treatment.